GHRP-6

In healthy human volunteers, the GH response to GHRP-6 was markedly attenuated when endogenous GHRH signaling was blocked (by somatostatin infusion or competitive antagonism), demonstrating that GHRP-6 does not act as a fully independent secretagogue. Maximal GH release required functional hypothalamic GHRH, indicating that GHRP-6 amplifies GH output largely through a GHRH-dependent, hypothalamic-level mechanism rather than acting solely at the pituitary.

This human study showed that GHRP-6 does not release growth hormone entirely on its own. It works mainly by boosting the body's own natural growth-hormone-releasing signal from the brain, and its effect is much weaker when that natural signal is blocked. In short, GHRP-6 amplifies an existing pathway rather than replacing it.

In children with normal (non-GH-deficient) short stature, orally administered GHRP-6 produced a significant rise in serum GH, with a response broadly comparable to that elicited by GHRH. The study documented that the hexapeptide retains GH-releasing bioactivity via the oral route, though with the lower potency expected relative to intravenous dosing.

This study gave GHRP-6 by mouth to children who were short but not growth-hormone deficient, and it raised their growth hormone levels similarly to a standard releasing hormone. It showed the peptide can still work when swallowed, not only when injected.

In a pig model of acute myocardial infarction, GHRP-6 (400 ug/kg) reduced infarct mass and wall thinning by roughly 78% and 50% respectively versus saline. Markers of oxidative stress indicated the peptide limited myocardial injury by lowering reactive oxygen species and preserving endogenous antioxidant defenses. The cytoprotective effect is attributed to signaling through receptors including CD36 and GHS-R1a, independent of its GH-releasing action. These are animal findings, not established human treatment.

In pigs given a simulated heart attack, GHRP-6 substantially shrank the area of damaged heart muscle compared with untreated animals, apparently by reducing harmful oxidative stress. This tissue-protecting effect seems separate from its role in releasing growth hormone. These are animal findings and have not been established as a treatment in humans.